Literature DB >> 3732891

Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid.

W Wellmann, P C Fink, F Benner, F W Schmidt.   

Abstract

Endotoxins in plasma were monitored during treatment in 18 patients hospitalised for acute exacerbation of Crohn's disease: systemic endotoxaemia was found on admission in all but one. The patients were randomly divided into two groups: one receiving treatment with total parenteral nutrition and steroids. To decrease the absorbable endotoxin pool, the other group was additionally treated with whole gut irrigation and 5-aminosalicylic acid was added to the lavage fluid. In most of these patients endotoxaemia cleared after intestinal lavage and they needed shorter hospitalisation. Earlier improvement was also indicated by a faster decrease of the Crohn's disease activity index and vanHees index. In the group receiving conservative treatment alone, endotoxaemia was controlled within three weeks. We conclude that endotoxaemia occurs in most patients suffering from active Crohn's disease. Control of endotoxaemia after intestinal lavage suggests that systemic endotoxaemia is caused by absorption of endotoxins from the gut. Earlier improvement after whole gut irrigation indicates its beneficial effect in active Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732891      PMCID: PMC1433583          DOI: 10.1136/gut.27.7.814

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  39 in total

1.  Intestinal lavage in the treatment of Crohn's disease: a pilot study.

Authors:  W Wellmann; F W Schmidt
Journal:  Klin Wochenschr       Date:  1982-04-01

2.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

3.  Ileal dysfunction and bacterial overgrowth in patients with Crohn's disease.

Authors:  P Rutgeerts; Y Ghoos; G Vantrappen; H Eyssen
Journal:  Eur J Clin Invest       Date:  1981-06       Impact factor: 4.686

Review 4.  Recent developments in nonspecific inflammatory bowel disease (second of two parts).

Authors:  J B Kirsner; R G Shorter
Journal:  N Engl J Med       Date:  1982-04-08       Impact factor: 91.245

5.  Limulus amebocyte lysate test for endotoxemia: investigations with a femtogram sensitive spectrophotometric assay.

Authors:  P C Fink; L Lehr; R M Urbaschek; J Kozak
Journal:  Klin Wochenschr       Date:  1981-03-02

6.  Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery.

Authors:  K R Palmer; B I Duerden; C D Holdsworth
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

7.  An index of inflammatory activity in patients with Crohn's disease.

Authors:  P A van Hees; P H van Elteren; H J van Lier; J H van Tongeren
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

8.  Agglutinins to bacteria in Crohn's disease.

Authors:  N Matthews; J F Mayberry; J Rhodes; L Neale; J Munro; F Wensinck; G H Lawson; A C Rowland; G A Berkhoff; S W Barthold
Journal:  Gut       Date:  1980-05       Impact factor: 23.059

9.  The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis.

Authors:  C P Willoughby; J Piris; S C Truelove
Journal:  Scand J Gastroenterol       Date:  1980       Impact factor: 2.423

Review 10.  Molecular basis of fever in humans.

Authors:  C A Dinarello; S M Wolff
Journal:  Am J Med       Date:  1982-05       Impact factor: 4.965

View more
  39 in total

Review 1.  Probiotics and inflammatory bowel disease.

Authors:  Daisy Jonkers; Reinhold Stockbrügger
Journal:  J R Soc Med       Date:  2003-04       Impact factor: 5.344

Review 2.  Intestinal epithelial barrier function and tight junction proteins with heat and exercise.

Authors:  Karol Dokladny; Micah N Zuhl; Pope L Moseley
Journal:  J Appl Physiol (1985)       Date:  2015-09-10

3.  Polymorphonuclear leucocytes in Crohn's disease and ulcerative proctocolitis: association between enhanced adherence to nylon fibre and disease variables.

Authors:  J Cason; C C Ainley; R A Wolstencroft; R P Thompson
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

Review 4.  Do probiotics have a therapeutic role in gastroenterology?

Authors:  Jimmy K Limdi; Catherine O'Neill; John McLaughlin
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

5.  Aortic thrombosis complicating Crohn disease: an unusual complication.

Authors:  Arshad Bashir Khan; Nadeem Bhat; Ammar Hassan; Ghaith Al Saied
Journal:  Can J Surg       Date:  2009-10       Impact factor: 2.089

6.  Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease.

Authors:  J Boudeau; A L Glasser; E Masseret; B Joly; A Darfeuille-Michaud
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14.

Authors:  Shuhong Guo; Rana Al-Sadi; Hamid M Said; Thomas Y Ma
Journal:  Am J Pathol       Date:  2012-11-29       Impact factor: 4.307

8.  Lipopolysaccharide-Induced Increase in Intestinal Permeability Is Mediated by TAK-1 Activation of IKK and MLCK/MYLK Gene.

Authors:  Meghali Nighot; Manmeet Rawat; Rana Al-Sadi; Eliseo F Castillo; Prashant Nighot; Thomas Y Ma
Journal:  Am J Pathol       Date:  2019-02-01       Impact factor: 4.307

9.  Significance of systemic endotoxaemia in inflammatory bowel disease.

Authors:  K R Gardiner; M I Halliday; G R Barclay; L Milne; D Brown; S Stephens; R J Maxwell; B J Rowlands
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

10.  Experimental colitis in rats induces low-grade endotoxinemia without hepatobiliary abnormalities.

Authors:  H S Brand; M A Maas; A Bosma; R J Van Ketel; P Speelman; R A Chamuleau
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.